Certara sells Regulatory & Medical Writing business to Veristat for up to $135M

Certara, Inc.

Cash consideration of $100M plus up to $35M earn-out based on future performance.
Sold business generated $50M revenue and $17M adjusted EBITDA in 2025, employing ~220 people.
Transaction expected to close in Q2 2026 subject to customary conditions.
Certara will update 2026 guidance after close; proceeds to be deployed for MIDD platform growth.
Sale sharpens focus on Model-Informed Drug Development and AI-integrated modeling.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Certara, Inc. entered into Purchase Agreement with Veristat, LLC and certain of its affiliates valued at $100 million (effective 2026-04-21).

Action: entry
Agreement: asset purchase
Counterparty: Veristat, LLC and certain of its affiliates
Value: $100 million
Effective: 2026-04-21

Exact text from the filing

On April 21, 2026, Certara, Inc. (the “Company”), together with certain of its subsidiaries, entered into a Purchase Agreement (the “Purchase Agreement”) with Veristat, LLC and certain of its affiliates (collectively, “Veristat”), pursuant to which the Company agreed to sell its global medical writing and related regulatory services business (the “Business”) to Veristat.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Certara, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-046358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.